L Capital Partners is a $165-million fund looking to advance companies with the potential to take groundbreaking products to market.
Business Model: B2B
Revenue: $17.8M
Employees: 51-200
Address: 10 E 53rd St
City: New York
State: NY
Zip: 10022
Country: US
L Capital Partners is a $165-million fund looking to advance companies with the potential to take groundbreaking products to market. This mission is clearly reflected in their portfolio of healthcare, technology and energy &a; environment companies with their unique value propositions. To help these companies realize the promise of transformational change they are a committed, multi-round investor that supports each company with a team of partners, principals and associates who have deep industry expertise and financial acumen. In the healthcare sector, they target investments in the areas of biopharmaceuticals and medical devices, and are particularly interested in companies in which the areas of drugs and devices intersect. In the technology sector, they primarily target companies in security/defense (homeland security) and information technology. The energy &a; environment sector is an emerging area for us, and, in general, they are looking for companies that could improve the quality of life.
Contact Phone:
+12126757755
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
10/2007 | Tengion | Series C | 33M |
6/2006 | Tengion | Series B | 50M |
4/2012 | Intrapace | Venture Round | 0 |
11/2008 | Evogen | Series B | 3M |
8/2005 | Tengion | Series A | 39M |
4/2009 | WiSpry | Series C | 0 |
6/2008 | Exenta | Series A | 4M |
4/2014 | Vicini | Venture Round | - |
11/2008 | Tengion | Series C | 0 |
12/2007 | Hi-G-Tek | Venture Round | 5.5M |
9/2008 | CeNeRx BioPharma | Series B | 15M |
7/2008 | Eleme Medical | Series C | 0 |
8/2010 | CeNeRx BioPharma | Series C | 0 |
8/2005 | Protez Pharmaceuticals | Series B | 15M |
2/2012 | CeNeRx BioPharma | Series D | 4.6M |
4/2007 | IntelliPath | Series A | 6.5M |
10/2015 | El Ganso.com | Venture Round | - |
5/2009 | iScience Interventional | Series F | 20.5M |
2/2007 | Locus Pharmaceuticals | Series E | 30.2M |
9/2006 | Hi-G-Tek | Venture Round | 10M |
11/2005 | CeNeRx BioPharma | Series A | 8M |
3/2008 | WiSpry | Series B | 0 |
10/2006 | WiSpry | Series B | 0 |
10/2015 | El Ganso.com | Venture Round | - |
4/2014 | Vicini | Venture Round | - |
4/2012 | Intrapace | Venture Round | 0 |
2/2012 | CeNeRx BioPharma | Series D | 0 |
8/2010 | CeNeRx BioPharma | Series C | 0 |
5/2009 | iScience Interventional | Series F | 0 |
4/2009 | WiSpry | Series C | 0 |
11/2008 | Tengion | Series C | 0 |
11/2008 | Evogen | Series B | 0 |
9/2008 | CeNeRx BioPharma | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|